We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules

AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448 million in disgorgement.

The decision hands the Federal Trade Commission a win in its first litigated case against a pharmaceutical company since the Supreme Court's landmark 2013 Actavis decision.

US District Judge Harvey Bartle III found that AbbVie’s precursor company — Unimed Pharmaceuticals, a unit of Solvay — and Besins filed frivolous patent litigation against...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@ftcwatch.com
Phone: 202-909-2156

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch